ZNTL

Zentalis Pharmaceuticals (ZNTL)

Zentalis Pharmaceuticals Inc

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:ZNTL

1 2 3 4 5 6 7 8 9 10 次へ >>

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/09/17	10 : 38	PR Newswire (US)	Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/09/16	20 : 02	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/09/16	20 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals Announces FDA Has Lifted Partial Clinical Hold on Azenosertib Studies	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/09/09	20 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals to Present Preclinical Azenosertib Data at ESMO 2024	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/09/04	05 : 40	GlobeNewswire Inc.	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/08/20	05 : 55	Business Wire	Newman Ferrara LLP Announces Corporate Governance Investigation of Zentalis Pharmaceuticals, Inc. – ZNTL	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/08/09	20 : 03	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/08/09	20 : 01	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/08/09	20 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals Reports Second Quarter 2024 Financial Results and Operational Progress	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/08/02	07 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/07/26	03 : 49	PR Newswire (US)	Kuehn Law Encourages Investors of Zentalis Pharmaceuticals, Inc. to Contact Law Firm	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/07/02	07 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/06/18	20 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/06/04	07 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/06/03	20 : 00	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/05/30	20 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/05/29	20 : 16	Edgar (US Regulatory)	Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/05/29	20 : 04	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/05/29	20 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/05/24	06 : 01	GlobeNewswire Inc.	Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/05/14	20 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals to Present at TD Cowen 5th Annual Oncology Innovation Summit	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/05/07	20 : 05	Edgar (US Regulatory)	Form 10-Q - Quarterly report [Sections 13 or 15(d)]	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/05/07	20 : 03	Edgar (US Regulatory)	Form 8-K - Current report	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/05/07	20 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Progress	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/05/02	06 : 30	GlobeNewswire Inc.	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/04/03	05 : 05	GlobeNewswire Inc.	Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/04/02	06 : 30	GlobeNewswire Inc.	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/03/02	08 : 00	GlobeNewswire Inc.	Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/03/01	07 : 20	Edgar (US Regulatory)	Form S-8 - Securities to be offered to employees in employee benefit plans	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc
2024/03/01	07 : 14	Edgar (US Regulatory)	Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers	NASDAQ:ZNTL	Zentalis Pharmaceuticals Inc